Constellation Pharmaceuticals, Inc. (CNST): Price and Financial Metrics

Constellation Pharmaceuticals, Inc. (CNST)

Today's Latest Price: $22.93 USD

0.51 (-2.18%)

Updated Dec 2 4:00pm

Add CNST to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CNST Stock Price Chart Interactive Chart >

Price chart for CNST

CNST Price/Volume Stats

Current price $22.93 52-week high $59.49
Prev. close $23.44 52-week low $17.00
Day low $22.26 Volume 317,270
Day high $23.39 Avg. volume 522,485
50-day MA $22.20 Dividend yield N/A
200-day MA $28.76 Market Cap 1.09B

Constellation Pharmaceuticals, Inc. (CNST) Company Bio

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company’s lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors and/or hematological malignancies; and CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. The company was founded in 2008 and is based in Cambridge, Massachusetts.

CNST Latest News Stream

Event/Time News Detail
Loading, please wait...

CNST Latest Social Stream

Loading social stream, please wait...

View Full CNST Social Stream

Latest CNST News From Around the Web

Below are the latest news stories about Constellation Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNST as an investment opportunity.

Constellation Pharmaceuticals: Myelofibrosis Treatment Win Can Still Happen - We'll Know Soon

Investment Thesis Constellation Pharmaceuticals (CNST) has proved to be something of an enigma for its shareholders to date. The company's shares spiked to a price of $50 in June as it seemed likely the company had a sure-fire path to approval for its lead candidate CPI-0610 based on preliminary data...

Edmund Ingham on Seeking Alpha | September 29, 2020

Constellation Pharma downgraded to Perform at Oppenheimer

Oppenheimer analyst Silvan Tuerkcan has downgraded Constellation Pharmaceuticals ([[CNST]] -4.0%) to Perform from Outperform, and lowered price target to $20 from $47 driven by new 25% Probability of Success versus prior 60% for its lead asset CPI-0610, in myelofibrosis, a rare bone marrow cancer.The analyst notes that the company plans...

Seeking Alpha | September 8, 2020

Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on August 5, 2020, to discuss its second quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 4372778. About Constellation PharmaceuticalsConstellation Pharmaceuticals is a clinical-stage biopharmac...

Yahoo | July 31, 2020

Did Hedge Funds Make The Right Call On Constellation Pharmaceuticals, Inc. (CNST) ?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | July 20, 2020

Steven Cohen Homes in on Otonomy

Guru ups bet in biotech focused on ear-related disorders Continue reading...

Yahoo | July 15, 2020

Read More 'CNST' Stories Here

CNST Price Returns

1-mo 16.40%
3-mo 7.35%
6-mo -38.67%
1-year -47.82%
3-year N/A
5-year N/A
YTD -51.33%
2019 1,074.81%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9817 seconds.